Elanco Animal Health Inc

Elanco Animal Health Incorporated (ELAN: NASDAQ) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company operates as a single segment within the animal health industry, offering a comprehensive portfolio marketed under approximately 200 brands sold in more than 90 countries. Elanco's website is www.elanco.com.

The company's product portfolio is divided into two primary categories: pet health and farm animal products. Pet health offerings focus on parasiticides, dermatology, vaccines, and pain therapeutics for dogs and cats, including flagship brands such as the Advantage Family, Seresto, Credelio Family, and Zenrelia. Farm animal products serve cattle, poultry, swine, and sheep producers through medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes, with key products including Rumensin, Maxiban, and Monteban. In 2025, the company's top five product families represented approximately 38 percent of total revenue, with the Advantage Family alone accounting for approximately 10 percent.

Geographically, the United States represents the company's largest market at 47 percent of total revenue, with Brazil, the United Kingdom, and China serving as the largest international markets. The company employs approximately 9,400 full-time employees and 500 fixed-duration employees globally, with approximately 30 percent of the workforce based in the United States.

Elanco operates a global manufacturing network comprising 16 internal sites and approximately 140 contract manufacturing organizations. The company maintains research and development centers of excellence across multiple continents, including facilities in Australia, Germany, India, Switzerland, Brazil, China, and the United States, with over 1,000 employees dedicated to R&D and regulatory affairs.

The company traces its heritage to 1954 as a business unit of Eli Lilly and Company, becoming independently incorporated in September 2018 with separation finalized in March 2019. A transformational acquisition of Bayer Animal Health in August 2020 marked the largest acquisition in industry history, enabling Elanco to become a more diverse, durable, and globally scaled organization with enhanced geographic and product portfolio balance.